The presence of SNPs in genes involved in the membrane transport of testosterone and dehydroepiandrosterone (DHEA), namely SLCO2B1 and SLCO1B3, has been reported as having an influence on the efficacy of androgen deprivation therapy (ADT) in prostate cancer [7]. This evidence concerns the gene SLCO1B3 and prostate carcinoma.